<DOC>
	<DOCNO>NCT00071006</DOCNO>
	<brief_summary>The study test safety efficacy axitinib patient hematologic disease Acute Myeloid Leukemia Myelodysplastic Syndrome . The study test patient poor prognosis enter study .</brief_summary>
	<brief_title>AG-013736 ( Axitinib ) In Patients With Poor Prognosis Acute Myeloid Leukemia ( AML ) Or Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Poor prognosis AML MDS Histological confirmation diagnosis White blood cell count less equal 30,000/mm3 Adequate hepatic renal function document within 14 day prior registration Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 No evidence preexist uncontrolled hypertension Not suitable candidate chemotherapy No prior systemic chemotherapy treatment AML MDS treatment antiangiogenesis agent Patients must exclusion criterion . Candidate chemotherapy Patients AML M3 ( acute promyelocytic leukemia ) Conditions might confound evaluation safety efficacy increase patient risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>